UNSPSC 51372205: Racemoramide

This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3J8QT828G, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as racemoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Racemoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10235MIG.

UNSPSC 51372205 Racemoramide is a Commodity code that nominally covers a specific pharmaceutical compound, but state and local procurement activity under this code does not reflect purchases of racemoramide itself. Instead, the recent solicitations tagged to this code involve broader pharmaceutical and health-related acquisitions: naloxone and drug deactivation systems for community health programs, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. The actual buying reflects public health agencies and cooperative purchasing alliances procuring emergency response medications, pharmacy benefit administration, and generic drug inventories rather than the narrow chemical compound the code name suggests. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across participating jurisdictions including Oregon). The code shows limited focus on racemoramide specifically and substantial mismatch between the code's nominal scope and what state and local governments are actually buying under it.

Recent activity spans Florida and Texas, with multistate cooperative purchasing activity centered on Minnesota administration but serving state and local facilities across multiple states. Representative opportunities include Seminole County's IFB60459723LAS (IFB posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness July 1, 2026. The code shows little relevant recent activity directly tied to racemoramide procurement.